{"id":10060,"date":"2021-05-27T15:27:21","date_gmt":"2021-05-27T22:27:21","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10060"},"modified":"2021-05-28T15:27:58","modified_gmt":"2021-05-28T22:27:58","slug":"effect-of-2-inactivated-sars-cov-2-vaccines-on-symptomatic-covid-19-infection-in-adults","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/27\/effect-of-2-inactivated-sars-cov-2-vaccines-on-symptomatic-covid-19-infection-in-adults\/","title":{"rendered":"Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The efficacy in preventing symptomatic COVID-19 14 days after the second dose for two inactivated SARS-CoV-2 vaccines (derived from strains WIV04 and HB02) was 73% (95% CI, 58%-82%) and 78% (95% CI, 65%-86%), respectively, in an interim analysis of a randomized, placebo-controlled phase 3 trial among adults aged \u226518 years without known prior infection in the United Arab Emirates and Bahrain (n=38,206). During a median follow-up of 77 days, symptomatic COVID-19 was identified in 26 participants in the WIV04 group (n=12,743), 21 in the HB02 group (n=12,726), and 95 in the control group (n=12,737). The country of origin of the participants included the UAE (24%), India (14%), Bangladesh (10%), China (10%), Pakistan (9%), Bahrain (7%), Egypt (5%), the Philippines (4%), Nepal (2%), and Syria (2%). Adverse reactions 7 days after each dose occurred in 42%-47% of participants, while serious adverse events occurred in \u22640.6% in all 3 groups.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Al Kaabi et al.\u00a0(May 26, 2021). Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. JAMA. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1001\/jama.2021.8565\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1001\/jama.2021.8565<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The efficacy in preventing symptomatic COVID-19 14 days after the second dose for two inactivated SARS-CoV-2 vaccines (derived from strains WIV04 and HB02) was 73% (95% CI, 58%-82%) and 78% (95% CI, 65%-86%), respectively, in an interim analysis of a randomized, placebo-controlled phase 3 trial among adults aged \u226518 years without known prior infection in&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/27\/effect-of-2-inactivated-sars-cov-2-vaccines-on-symptomatic-covid-19-infection-in-adults\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[142],"topic":[31],"class_list":["post-10060","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccine","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10060"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10060\/revisions"}],"predecessor-version":[{"id":10061,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10060\/revisions\/10061"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10060"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}